**6.3 Ibrutinib (Imbruvica)**

Is a small molecule targeted drug that acts as an irreversible burton tyrosine kinase inhibitor (BTK) and can be used to treat chronic lymphocytic leukemia (CLL). In 2013 FDA approved ibrutinib for treatment patients with mantle cell lymphoma and in 2013 also approved for CLL and small lymphocytic lymphoma with 17p [48, 49].
